purin 和pyrimidine衍生物的抗癌潜力和结构活性研究:一个更新的审查
Tanushree Manna1, Sumit Maji1, Mousumi Maity1
1Department of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Molecular diversity
|June 10, 2024
概括
新的抗癌药物正在使用 purin 和 pyrimidine 化合物进行开发. 这些异环分子对各种癌症表现出强大的活性,为更有效的癌症治疗提供了希望.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 在瘤学瘤学.
背景情况:
- 尽管进行了广泛的研究,癌症仍然是全球领先的健康挑战.
- 新型治疗策略对于有效的癌症药物设计和发现至关重要.
- purin 和 pyrimidine 异环化合物在向各种癌症方面表现有前途.
研究的目的:
- 审查新型 purin 和 pyrimidine 含有抗癌剂的合成策略.
- 为了突出这些化合物的结构-活性关系.
- 讨论他们克服药物耐药性的潜力.
主要方法:
- 最近 (过去十年) 关于 purin 和 pyrimidine 衍生物的文献综述研究.
- 合成路径和结构-活动关系的分析.
- 收集有关抗癌活性的数据,包括IC50值.
主要成果:
- 许多 purin 和 pyrimidine 衍生物具有强大的抗癌活性.
- 包含这些异环的化合物对向蛋白具有更强的疗效.
- 许多衍生品在纳米分子范围内达到IC50值.
结论:
- purin 和 pyrimidine 衍生物代表了一类有前途的抗癌药物.
- 它们与其他异环化合物的结合产生了对抗耐药癌症有效的新型分子.
- 本综述支持药物化学家开发下一代化疗药物.
相关概念视频
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Basicity of Heterocyclic Aromatic Amines
5.9K
Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
5.9K


